Since SARB targeted the CSC-related WNT/ß-Catenin and PI3K/AKT-signaling pathways36, we next focused on the most common stem cell marker in CRC, namely CD133 (PROM1), which was found to be significantly down-regulated by 5-FU, Combi, and SARB treatment in both cell lines (Fig. 4A, B). Here, SAR1B is linked to colorectal carcinoma.